Astrazeneca vaccine is effective against UK COVID-19 variant
Oxford University said on Friday that a clinical trial has shown that a vaccine it developed with Astrazeneca PLC worked against a more transmissible variant of the coronavirus first identified in the United Kingdom.
The efficacy of the vaccine against the UK variant of the coronavirus was 75 percent, compared with 84 percent for older variants.
The UK, South African and Brazilian variants of the coronavirus are now in the United States and elsewhere in the world, and there have been questions about whether the vaccine will work against them as well.
Simon Ateba is Chief White House Correspondent for Today News Africa. Simon covers President Joe Biden, Vice President Kamala Harris, the U.S. government, the United Nations, the International Monetary Fund, the World Bank and other financial and international institutions in Washington D.C. and New York City.
